Cargando…

Hepatotoxicity with cholestatic pattern secondary to enoxaparin treatment

OBJECTIVES: Treatment with low-molecular-weight heparins is very common in clinical practice. Exceptionally, some patients develop hepatitis within a few days of starting treatment, and rapid discontinuation of the drug is decisive to avoid chronification. CASE PRESENTATION: These episodes usually p...

Descripción completa

Detalles Bibliográficos
Autores principales: Velasco de Cos, Guillermo, Sánchez-Molina Acosta, Isabel, Iturralde Ros, Marta, Maiztegi Azpitarte, Ainhoa, Moyano Martinez, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197442/
https://www.ncbi.nlm.nih.gov/pubmed/37360893
http://dx.doi.org/10.1515/almed-2021-0048
_version_ 1785044553139486720
author Velasco de Cos, Guillermo
Sánchez-Molina Acosta, Isabel
Iturralde Ros, Marta
Maiztegi Azpitarte, Ainhoa
Moyano Martinez, Ana
author_facet Velasco de Cos, Guillermo
Sánchez-Molina Acosta, Isabel
Iturralde Ros, Marta
Maiztegi Azpitarte, Ainhoa
Moyano Martinez, Ana
author_sort Velasco de Cos, Guillermo
collection PubMed
description OBJECTIVES: Treatment with low-molecular-weight heparins is very common in clinical practice. Exceptionally, some patients develop hepatitis within a few days of starting treatment, and rapid discontinuation of the drug is decisive to avoid chronification. CASE PRESENTATION: These episodes usually present themselves only with elevated transaminases. We describe the case of a patient who presented a cholestatic pattern, which is very uncommon with this type of drug. CONCLUSIONS: Hepatitis secondary to heparin therapy is an underdiagnosed entity. The laboratory plays a fundamental role in its diagnosis, given that it initially presents itself without a clear clinical profile.
format Online
Article
Text
id pubmed-10197442
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher De Gruyter
record_format MEDLINE/PubMed
spelling pubmed-101974422023-06-23 Hepatotoxicity with cholestatic pattern secondary to enoxaparin treatment Velasco de Cos, Guillermo Sánchez-Molina Acosta, Isabel Iturralde Ros, Marta Maiztegi Azpitarte, Ainhoa Moyano Martinez, Ana Adv Lab Med Case Report OBJECTIVES: Treatment with low-molecular-weight heparins is very common in clinical practice. Exceptionally, some patients develop hepatitis within a few days of starting treatment, and rapid discontinuation of the drug is decisive to avoid chronification. CASE PRESENTATION: These episodes usually present themselves only with elevated transaminases. We describe the case of a patient who presented a cholestatic pattern, which is very uncommon with this type of drug. CONCLUSIONS: Hepatitis secondary to heparin therapy is an underdiagnosed entity. The laboratory plays a fundamental role in its diagnosis, given that it initially presents itself without a clear clinical profile. De Gruyter 2021-11-03 /pmc/articles/PMC10197442/ /pubmed/37360893 http://dx.doi.org/10.1515/almed-2021-0048 Text en © 2021 Guillermo Velasco de Cos et al., published by De Gruyter, Berlin/Boston https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License.
spellingShingle Case Report
Velasco de Cos, Guillermo
Sánchez-Molina Acosta, Isabel
Iturralde Ros, Marta
Maiztegi Azpitarte, Ainhoa
Moyano Martinez, Ana
Hepatotoxicity with cholestatic pattern secondary to enoxaparin treatment
title Hepatotoxicity with cholestatic pattern secondary to enoxaparin treatment
title_full Hepatotoxicity with cholestatic pattern secondary to enoxaparin treatment
title_fullStr Hepatotoxicity with cholestatic pattern secondary to enoxaparin treatment
title_full_unstemmed Hepatotoxicity with cholestatic pattern secondary to enoxaparin treatment
title_short Hepatotoxicity with cholestatic pattern secondary to enoxaparin treatment
title_sort hepatotoxicity with cholestatic pattern secondary to enoxaparin treatment
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197442/
https://www.ncbi.nlm.nih.gov/pubmed/37360893
http://dx.doi.org/10.1515/almed-2021-0048
work_keys_str_mv AT velascodecosguillermo hepatotoxicitywithcholestaticpatternsecondarytoenoxaparintreatment
AT sanchezmolinaacostaisabel hepatotoxicitywithcholestaticpatternsecondarytoenoxaparintreatment
AT iturralderosmarta hepatotoxicitywithcholestaticpatternsecondarytoenoxaparintreatment
AT maiztegiazpitarteainhoa hepatotoxicitywithcholestaticpatternsecondarytoenoxaparintreatment
AT moyanomartinezana hepatotoxicitywithcholestaticpatternsecondarytoenoxaparintreatment